Entelos Overview
- Year Founded
-
1996
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Financing Rounds
-
6
- Investments
-
1
Entelos General Information
Description
Developer of predictive bio-simulation technologies intended to enhance the discovery, development and utilization of medicines. The company's bio-simulation technologies offers advanced predictive technologies that dramatically lower the risk, time, and cost of product development in the pharmaceutical, healthcare, nutrition and consumer markets while its in depth systems biology data models, virtual patient and population human technology provide highly predictive analyses to assist its customers develop safer and more effective drugs, foods and consumer products.
Contact Information
Website
www.entelos.comCorporate Office
- Two Waters Park Drive
- Suite 200
- San Mateo, CA 94403
- United States
Corporate Office
- Two Waters Park Drive
- Suite 200
- San Mateo, CA 94403
- United States
Entelos Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Entelos Comparisons
Industry
Financing
Details
Entelos Competitors (10)
One of Entelos’s 10 competitors is Charles River Laboratories International, a Formerly PE-Backed company based in Wilmington, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Charles River Laboratories International | Formerly PE-Backed | Wilmington, MA | ||||
| Cyclenium Pharma | Corporate Backed or Acquired | Montreal, Canada | ||||
| Ambry Genetics | Formerly PE-Backed | Aliso Viejo, CA | ||||
| Progentec | Venture Capital-Backed | Oklahoma City, OK | ||||
| Mission Therapeutics | Venture Capital-Backed | Cambridge, United Kingdom |
Entelos Patents
Entelos Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2010148411-A1 | Method and apparatus for computer modeling hypertension | Inactive | 19-Jun-2009 | ||
| US-20100120050-A1 | Biomarkers for assessing altherosclerotic potential | Inactive | 11-Nov-2008 | ||
| AU-2009314145-A1 | Biomarkers for assessing atherosclerotic potential | Inactive | 11-Nov-2008 | ||
| EP-2350643-A1 | Biomarkers for assessing atherosclerotic potential | Inactive | 11-Nov-2008 | ||
| EP-2350643-A4 | Biomarkers for assessing atherosclerotic potential | Inactive | 11-Nov-2008 | C12Q1/6883 |
Entelos Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Entelos Acquisitions (1)
Entelos’s most recent deal was a Merger/Acquisition with Iconix Biosciences for . The deal was made on 31-Aug-2007.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Iconix Biosciences | 31-Aug-2007 | Merger/Acquisition | Information Services (B2C) |
Entelos FAQs
-
When was Entelos founded?
Entelos was founded in 1996.
-
Where is Entelos headquartered?
Entelos is headquartered in San Mateo, CA.
-
What industry is Entelos in?
Entelos’s primary industry is Discovery Tools (Healthcare).
-
Is Entelos a private or public company?
Entelos is a Private company.
-
What is Entelos’s current revenue?
The current revenue for Entelos is .
-
How much funding has Entelos raised over time?
Entelos has raised $34.6M.
-
Who are Entelos’s investors?
Abingworth, Activant Capital, Boulder Ventures, Brentwood Venture Capital, and CRV are 5 of 11 investors who have invested in Entelos.
-
Who are Entelos’s competitors?
Charles River Laboratories International, Cyclenium Pharma, Ambry Genetics, Progentec, and Mission Therapeutics are some of the 10 competitors of Entelos.
-
When was Entelos acquired?
Entelos was acquired on 07-Jan-2014.
-
Who acquired Entelos?
Entelos was acquired by Rosa & Co.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process